Precision BioSciences, Inc. (DTIL) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2021)
DTIL's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
DTIL Revenue Analysis (2016–2024)
As of February 28, 2026, Precision BioSciences, Inc. (DTIL) generated trailing twelve-month (TTM) revenue of $698,000, reflecting significant decline in growth of -97.7% year-over-year. The most recent quarter (Q3 2025) recorded $13,000 in revenue, down 27.8% sequentially.
Looking at the longer-term picture, DTIL's 5-year compound annual growth rate (CAGR) stands at +25.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $115.5 million in 2021.
Revenue diversification analysis shows DTIL's business is primarily driven by Therapeutics Segment (97%), and Food Segment (3%). With over half of revenue concentrated in Therapeutics Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), DTIL has underperformed the peer group in terms of revenue growth. Compare DTIL vs ALNY →
Peer Comparison
Compare DTIL's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DTILCurrent | $698,000 | -97.7% | +25.3% | -38.1% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $68.7M | +41.0% | $68.7M | 100.0% | $-26,162,000 | -38.1% |
| 2023 | $48.7M | +94.1% | $48.7M | 100.0% | $-43,736,000 | -89.8% |
| 2022 | $25.1M | -78.3% | $25.1M | 100.0% | $-62,308,000 | -248.3% |
| 2021 | $115.5M | +375.7% | $115.5M | 100.0% | $-39,376,000 | -34.1% |
| 2020 | $24.3M | +9.2% | $24.3M | 100.0% | $-109,828,000 | -452.2% |
| 2019 | $22.2M | +104.3% | $22.2M | 100.0% | $-87,204,000 | -392.1% |
| 2018 | $10.9M | +67.8% | $10.9M | 100.0% | $-47,912,000 | -440.2% |
| 2017 | $6.5M | -7.6% | $6.5M | 100.0% | $-21,974,000 | -338.9% |
| 2016 | $7.0M | - | $7.0M | 100.0% | $-8,828,000 | -125.8% |
See DTIL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DTIL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare DTIL vs AGIO
See how DTIL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is DTIL's revenue growth accelerating or slowing?
DTIL revenue declined -97.7% year-over-year, contrasting with the 5-year CAGR of +25.3%. TTM revenue fell to $698000.00. This reverses the prior growth trend.
What is DTIL's long-term revenue growth rate?
Precision BioSciences, Inc.'s 5-year revenue CAGR of +25.3% reflects the variable expansion pattern. Current YoY growth of -97.7% is below this long-term average.
How is DTIL's revenue distributed by segment?
DTIL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.